Radiotherapy. Treatment of illnesses by way of radiations for the purpose of stopping the proliferation of malignant cells.
Radiotherapy. If none of the above treatments are possible for medical reasons, the tumour must have resulted in permanent neurological damage. Tumours or lesions in the pituitary gland are not covered.
Radiotherapy. External beam radiotherapy was administered to the pelvis using a four-field box technique. Patients were treated with 10 MV photons from a linear accelerator to a total dose of 46 Gy in 2 Gy fractions, specified at the isocentre. A brachytherapy boost was given to the vaginal vault in case of extensive CLS (68% of the patients), using vaginal colpostats, 15 Gy low dose rate or equivalent dose, prescribed at 5 mm from the vaginal mucosa. The follow-up was closed on April 2005 and ranged for the 402 patients from 0 to 223 months. The mean duration of follow-up was 60 months. The mean and median duration of follow-up for the 51 HR patients was 54 and 40 months, respectively; with adjuvant radiotherapy 50 and 38 months and without radiotherapy 59 and 58 months, respectively. The disease free survival (DFS) was defined as the time from RHL to cytologically or histologically proven evidence of recurrent disease or date last seen. Cancer specific survival (CSS) was defined as the time from date of operation to death by tumour or date last seen. Survival curves were made using the Xxxxxx-Xxxxx method (25). The difference in DFS and CSS by treatment regimen was evaluated using the log-rank test (25;26). The chi-square test was used to calculate the relative risk and a p-value <0.05 was considered as statistically significant. Results Fifty-one (13%) patients met the LUMC criteria for postoperative radiotherapy. The clinical and histo- logical characteristics of the HR patients who were treated with (n=34, 67%; after 1997) and without postoperative radiotherapy (n=17, 33%; before 1997 or protocol violation after 1997) are listed in Table
Radiotherapy. Private room (difference between semi-private and private room)
Radiotherapy. Radiotherapy including when it is used to relieve pain ✓ Yes A type of radiation therapy which uses protons rather than x-rays to treat cancer. ✓ Yes We will pay PBT for: • malignant solid cancers in members aged 21 and under • central nervous system (brain and spinal cord) cancer • chordomas or chondrosarcomas (types of spine cancer) in the base of the skull or cervical spine (neck bones) which have not spread (metastasised) • high naso-ethmoid, frontal and sphenoid tumours with base of skuill involvement • adenoid cystic carcinoma with perineural invasion • esthesioneuriblastoma • cancer of the iris, ciliary body or choroid parts of the eye (uveal melanoma) which has not spread (metastasised) • conjunctival melanoma • choroidal haemangioma Accelerated charged particle therapies A therapy where charged particles are targeted into the tumor tissue at an increased speed. X No However, there is limited cover for Proton Beam Therapy in the circumstances shown above. Advanced Therapy Medicinal Products (ATMPs), Cellular and Gene Therapy Products (CGTPs) and Regenerative Medicine Advanced Therapy (RMAPs) Advanced Therapy Medicinal Products (ATMPs), Cellular and Gene Therapy Products (CGTPs) and Regenerative Medicine Advanced Therapy (RMAPs) ✓ Yes We cover a small number of approved ATMPs/CGTPs/RMATs. For the current list of ATMPs/CGTPs/RMATs that we cover, please see section 12. Care to relieve pain or symptoms rather than cure the cancer. ✓ Yes We will provide cover and support throughout your cancer treatment even if it becomes incurable. We cover radiotherapy, chemotherapy and surgery (such as draining fluid or inserting a stent) to relieve pain. End of life care ✓ Yes We will cover treatment to relieve symptoms during the end stages of life.
Radiotherapy. The following is the minimum list of equipment for sites to offer the complete comprehensive clinical training program in radiotherapy medical physics: • Positioning/Immobilization systems (breast, head and neck) • Mould room and workshop equipment • Conventional/fluoroscopic radiotherapy simulation • CT-based 3D treatment planning, including access to a CT scanner • 60Co teletherapy • Linear accelerator (LINAC) with photon and electron beams • Kilovoltage therapy • Brachytherapy low dose rate (LDR) and/or high dose rate (HDR) • Access to systems for absolute and relative dosimetry of all treatment equipment The assumption is that there is a workload of at least 500 new patients per year, 200 of whom will receive brachytherapy. In addition to the CQMPs, there should be sufficient staffing levels of radiation oncologists and radiation therapy technologists to support the service. At least 15% of the patients should receive individualized CT-based 3D treatment planning. From the list of equipment it is clear that there is a significant component of radiology procedures (radiographic, fluoroscopic and tomographic) needed for patient imaging as part of the treatment planning and treatment verification process. Some of the competencies gained during training on the physical and technical aspects of these modalities will meet the requirements for some modules of clinical training in radiology and nuclear medicine medical physics. References to the imaging medical physics competencies are noted in the portfolio where applicable.
